John Axelson
About John Axelson
John Axelson is a Cell Therapy (CAR T) Account Manager at Bristol-Myers Squibb in Oregon, responsible for achieving commercial objectives and coordinating resources for CAR T treatment sites.
Current Role at Bristol-Myers Squibb
John Axelson is currently working as a Cell Therapy (CAR T) Account Manager at Bristol-Myers Squibb, specifically in Oregon. In this role, he has been instrumental in achieving commercial objectives for the launches in Cell Therapy through detailed account planning, execution, and collaboration with various stakeholders. He serves as the main point of contact for CAR T treatment sites, leading the development of site-specific account plans. His responsibilities also include coordinating the deployment of resources tailored to meet customer needs in the rapidly advancing field of Cell Therapy. John has been in this position since January 2020.
Previous Experience at Pharmaceuticals
Before joining Bristol-Myers Squibb, John Axelson worked at Pharmaceuticals as a District Sales Manager from 1999 to 2015. Over his 16-year tenure, he was responsible for managing sales operations, and his leadership contributed to the growth and success of the district. His extensive experience in sales management positioned him as a key player in the pharmaceutical sales industry.
Experience at Organon Pharmaceuticals
John Axelson began his career at Organon Pharmaceuticals, where he worked as a Hospital Sales Representative from 1990 to 1997. During his 7 years with Organon, based in Orlando, Florida, John honed his skills in pharmaceutical sales and built strong relationships within the healthcare community. This foundational experience laid the groundwork for his successful career in the pharmaceutical industry.
Educational Background
John Axelson has a strong academic background that supports his professional achievements. He earned a Master’s degree from Florida State University, completing his studies from 1987 to 1988. Before that, he obtained a Bachelor's degree from Washington State University, where he studied from 1982 to 1986. His education has provided him with a substantial knowledge base and skill set that he has applied throughout his career in the pharmaceutical and cell therapy fields.